Synthesis of resorcylic acid lactones useful as therapeutic agents

Abstract

Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

1 - 36 . (canceled) 
     
     
         37 . A compound of formula II or II′, or a tautomer thereof, a pharmaceutically acceptable salt, solvate, ester or prodrug thereof: 
       
         
           
           
               
               
           
         
         wherein:
 X is O, S or NR; 
 Y is —OR, —O—(CH 2 ) m COOR, —O—(CH 2 ) m CON(R) 2 , —N(R) 2 , —N(R)SOR or —N(R)SO 2 R, wherein the groups bound to the nitrogen atom may be in Z- or E-configuration; 
 R 1  and R 2  are independently hydrogen, halogen, OR, N(R) 2 , SR, azido, nitro, cyano, aliphatic, aryl, alkylaryl, arylalkyl, heterocyclyl, heteroaryl, —S(O)R, —S(O) 2 R, —SO 2 N(R) 2 , —N(R)SO 2 R, —N(CO)R, —N(CO)N(R) 2 , —N(CO)OR, —O(CO)R, —(CO)R, —(CO)OR, —(CO)N(R) 2 , —O(CO)OR, or —O(CO)N(R) 2 ; 
 
         R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9  and R 10  are independently hydrogen, halogen, azido, nitro, cyano, aliphatic, alkylaryl, aralkyl, aryl, heteroalkyl, alkylheteroaryl, heterocyclyl, heteroaryl, OR, N(R) 2 , SR, —O(CH 2 ) m N(R)C(O)(CH 2 ) p R, —O(CH 2 ) m OC(O)(CH 2 ) p R, —O(CH 2 ) m C(O)(CH 2 ) p N(R) 2 , —O(CH 2 ) m C(O)(CH 2 ) p OR, —O(CH 2 ) m N(R)C(O)(CH 2 ) p OR, —O(CH 2 ) m N(R)C(O)(CH 2 ) p N(R) 2 , —O(CH 2 ) m OC(O)(CH 2 ) p OR, —O(CH 2 ) m OC(O)(CH 2 ) p N(R) 2 , —NR(CH 2 ) m N(R)C(O)(CH 2 ) p R, —NR(CH 2 ) m OC(O)(CH 2 ) p R, —NR(CH 2 ) m C(O)(CH 2 ) p N(R) 2 , —NR(CH 2 ) m C(O)(CH 2 ) p OR, —NR(CH 2 ) m N(R)C(O)(CH 2 ) p OR, —NR(CH 2 ) m N(R)C(O)(CH 2 ) p N(R) 2 , —NR(CH 2 ) m OC(O)(CH 2 ) p OR, —NR(CH 2 ) m OC(O)(CH 2 ) p N(R) 2 , —(CH 2 ) m N(R)C(O)(CH 2 ) p R, —(CH 2 ) m OC(O)(CH 2 ) p R, —(CH 2 ) m C(O)(CH 2 ) p N(R) 2 , —(CH 2 ) m C(O)(CH 2 ) p OR, —(CH 2 ) m N(R)C(O)(CH 2 ) p OR, —(CH 2 ) m N(R)C(O)(CH 2 ) p N(R) 2 , —(C H 2 ) m OC(O)(CH 2 ) p OR, —(CH 2 ) m OC(O)(CH 2 ) p N(R) 2 , —(CH 2 ) m N 3 , —O(CH 2 ) m N 3 —(CH 2 ) m N(R) 2 , —(C H 2 ) m OR, —(CH 2 ) m S(O)(CH 2 ) p R, —(CH 2 ) m S(O) 2 (CH 2 ) p R, —(CH 2 ) m SO 2 (CH 2 ) p N(R) 2 , or —(CH 2 ) m N(R)SO 2 (CH 2 ) p R; and
 each R is independently R 11 , hydrogen, aliphatic, amino, azido, cyano, nitro, alkylamino, dialkylamino, OH, alkoxy, carbonylamino, aminocarbonyl, alkoxycarbonyl, carbonyloxy, carboxy, acyl, aryl, alkaryl, arylalkyl including benzyl, heteroalkyl, heteroaryl, heterocyclyl, or a protecting group; or two R on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclic or heteroaryl ring; wherein where a group contains more than one R substituent; wherein R is optionally substituted, and each R can be the same or different; 
 R 11  is the group: 
 
       
       
         
           
           
               
               
           
         
       
       where Z is an inorganic or organic counterion;
 m and p are independently 0, 1, 2, 3, 4 or 5; wherein in formula II′, when X is O, then at least one of R 5 , R 6 , R 7 , R 8 , R 9  or R 10  is not hydrogen. 
 
     
     
         38 . The compound of  claim 37 , wherein X is O or NR. 
     
     
         39 . The compound of  claim 37 , wherein X is O or NR; and Y is —OR, —O—(CH 2 ) m COOR or —O—(CH 2 ) m CON(R) 2 . 
     
     
         40 . The compound of  claim 37 , wherein R 1  and R 2  are independently hydrogen or halogen. 
     
     
         41 . The compound of  claim 37 , wherein R 3  and R 4  are independently alkyl or hydrogen. 
     
     
         42 . The compound of  claim 37 , wherein, R 9  and R 10  are independently hydrogen or aliphatic. 
     
     
         43 . A pharmaceutical composition comprising particles comprising an effective HSP 90-inhibiting amount of a compound of  claim 37 , in combination with a pharmaceutically acceptable carrier. 
     
     
         44 . A pharmaceutical composition comprising particles comprising an effective kinase-inhibiting amount of a compound of  claim 37 , in combination with a pharmaceutically acceptable carrier. 
     
     
         45 . The pharmaceutical composition of  claim 43 , wherein the particles are less than about 2 microns average particle size. 
     
     
         46 . The pharmaceutical composition of  claim 44 , wherein the particles are less than about 2 microns average particle size. 
     
     
         47 . The pharmaceutical composition of  claim 43 , wherein the carrier is suitable for oral, parenteral, inhalation, topical, or intradermal administration. 
     
     
         48 . The pharmaceutical composition of  claim 44 , wherein the carrier is suitable for oral, parenteral, inhalation, topical, or intradermal administration. 
     
     
         49 . A method of treating a patient with a disease comprising administering to the patient with the disease an effective amount of a compound of  claim 37 , wherein the disease is an autoimmune disease, inflammatory disease, neurological or neurodegenerative disease, cancer, cardiovascular disease, allergy, asthma, or a hormone-related disease. 
     
     
         50 . The compound of  claim 37 , wherein R 7  is —OH.